

# Leo Luznik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11218617/publications.pdf>

Version: 2024-02-01

147  
papers

12,387  
citations

22153

59  
h-index

26613

107  
g-index

154  
all docs

154  
docs citations

154  
times ranked

7996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.4	4
2	Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. <i>Blood</i> , 2022, 139, 608-623.	1.4	42
3	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 356-368.	1.6	79
4	BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. <i>Blood</i> , 2022, 139, 2983-2997.	1.4	6
5	PTCy and "The Story of the Three Bears" Bone Marrow Transplantation, 2021, 56, 765-766.	2.4	2
6	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	1.2	24
7	National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	1.6	90
8	Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1021.e1-1021.e5.	1.2	15
9	Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 909.e1-909.e6.	1.2	7
10	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 616-629.	5.0	41
11	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	1.2	4
12	Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 223-223.	1.4	1
13	Treatment of AML Relapse After Allo-HCT. <i>Frontiers in Oncology</i> , 2021, 11, 812207.	2.8	16
14	Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. <i>Bone Marrow Transplantation</i> , 2020, 55, 40-47.	2.4	31
15	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 12-24.	2.4	94
16	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1563-1576.	7.2	17
17	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 502-508.	2.0	9
18	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2075-2081.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. <i>Lancet HIV</i> ,the, 2020, 7, e602-e610.	4.7	11
20	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2020, 4, 5078-5088.	5.2	23
21	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	5.2	52
22	Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2306-2310.	2.0	8
23	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. <i>Blood Advances</i> , 2020, 4, 1770-1779.	5.2	92
24	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1679-1688.	2.0	25
25	Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 636.	4.8	27
26	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020, 135, 28-40.	1.4	14
27	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
28	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2431-2437.	2.0	54
29	Post-transplantation cyclophosphamide for chimerism-based tolerance. <i>Bone Marrow Transplantation</i> , 2019, 54, 769-774.	2.4	15
30	Immune reconstitution after T-cell replete HLA-haploidentical transplantation. <i>Seminars in Hematology</i> , 2019, 56, 221-226.	3.4	29
31	T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 868-882.	2.0	15
32	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. <i>Lancet Haematology</i> ,the, 2019, 6, e183-e193.	4.6	111
33	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	30.7	253
34	Targeting PI3KÎ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	4.7	9
35	How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. <i>Blood</i> , 2019, 134, 1802-1810.	1.4	42
36	PTCY keeps on giving!. <i>Blood</i> , 2019, 134, 848-849.	1.4	3

#	ARTICLE	IF	CITATIONS
37	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019, 3, 2581-2585.	5.2	27
38	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. <i>Blood Advances</i> , 2019, 3, 2608-2616.	5.2	20
39	Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity. <i>Journal of Immunotherapy</i> , 2019, 42, 73-80.	2.4	2
40	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1128-1135.	2.0	38
41	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	1.4	21
42	Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. <i>Journal of Clinical Investigation</i> , 2019, 129, 2189-2191.	8.2	11
43	How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 513-521.	2.5	19
44	Systemic depletion of lymphocytes following focal radiation to the brain in a murine model. <i>OncImmunology</i> , 2018, 7, e1445951.	4.6	15
45	Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1108-1110.	2.0	7
46	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1022-1028.	2.0	29
47	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1099-1102.	2.0	61
48	Have haploidentical transplants replaced umbilical cord transplants for acute leukemias?. <i>Current Opinion in Hematology</i> , 2018, 25, 103-111.	2.5	18
49	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
50	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 521-534.	2.4	168
51	Haploidentical Transplants: Immune Reconstitution With and Without Augmentation Strategies. , 2018, , 271-289.		0
52	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. <i>Clinical Cancer Research</i> , 2018, 24, 3519-3527.	7.0	80
53	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 343-352.	2.0	61
54	Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 666-677.	2.0	45

#	ARTICLE	IF	CITATIONS
55	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2056-2064.	2.0	32
56	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	123
57	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	1.4	164
58	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 612-617.	2.0	17
59	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 391-400.	3.5	152
60	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- $\beta$ production. <i>Blood</i> , 2017, 129, 2570-2580.	1.4	122
61	Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 932-940.	3.5	27
62	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. <i>Blood</i> , 2017, 129, 1389-1393.	1.4	69
63	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1903-1909.	2.0	14
64	Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1887-1894.	2.0	42
65	Notching up B-cell pathology in chronic GVHD. <i>Blood</i> , 2017, 130, 2053-2054.	1.4	0
66	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
67	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 325-332.	2.0	61
68	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2017, 1, 288-292.	5.2	84
69	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. <i>Blood Advances</i> , 2017, 1, 652-661.	5.2	84
70	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. <i>Current Drug Targets</i> , 2017, 18, 315-331.	2.1	39
71	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	1.4	145
72	Might haplo be the (better) match?. <i>Blood</i> , 2016, 127, 799-800.	1.4	5

#	ARTICLE	IF	CITATIONS
73	For Whom the Bell Tolls: Programmed Death 1 as a Marker of Post-Transplantation Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2115-2116.	2.0	0
74	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016, 128, 1013-1017.	1.4	95
75	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. <i>Blood</i> , 2016, 127, 352-359.	1.4	29
76	Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow. <i>Transplantation</i> , 2016, 100, e140-e146.	1.0	5
77	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. <i>Journal of Hematology and Oncology</i> , 2016, 9, 35.	17.0	78
78	OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 27-35.	2.2	52
79	Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. <i>Seminars in Hematology</i> , 2016, 53, 90-97.	3.4	118
80	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2016, 57, 666-675.	1.3	11
81	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 112-118.	2.0	37
82	Modern approaches to HLA-haploidentical blood or marrow transplantation. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 10-24.	27.6	262
83	Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. <i>JCI Insight</i> , 2016, 1, .	5.0	111
84	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	1.4	101
85	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	1.4	259
86	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	1.4	565
87	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. <i>Science Translational Medicine</i> , 2015, 7, 288ra78.	12.4	104
88	Comparable and Robust Immune Reconstitution after HLA-Haploidentical or HLA-Matched Allogeneic Transplantation (BMT) Utilizing Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S71.	2.0	8
89	Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S29.	2.0	9
90	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2115-2122.	2.0	26

#	ARTICLE	IF	CITATIONS
91	Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 232-242.	3.4	20
92	Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent. <i>Oncolmmunology</i> , 2015, 4, e974393.	4.6	21
93	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <i>Journal of Clinical Oncology</i> , 2015, 33, 3152-3161.	1.6	215
94	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	8.2	173
95	Sustained CD4 <sup>+</sup> T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. <i>Oncolmmunology</i> , 2014, 3, e27357.	4.6	62
96	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 314-318.	2.0	103
97	Expertsâ€™ considerations on HLA-haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 187-197.	2.2	24
98	Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning. <i>Journal of Clinical Oncology</i> , 2014, 32, 3497-3505.	1.6	234
99	Are Alternative Donors Really Still "Alternative"? <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1463-1464.	2.0	3
100	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	1.4	179
101	Rarity of Donor-Derived Malignancy after Allogeneic BMT with High-Dose Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S252.	2.0	4
102	Donor CD4 <sup>+</sup> Foxp3 <sup>+</sup> regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. <i>Blood</i> , 2014, 124, 2131-2141.	1.4	162
103	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014, 124, 3817-3827.	1.4	165
104	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. <i>Blood</i> , 2014, 124, 535-535.	1.4	2
105	A Selective and Potent Rock 2 Inhibitor (KDO25) Decreases Human STAT3-Dependent IL-21 and IL-17 Production and Experimental Chronic Graft-Versus-Host Disease (cGVHD). <i>Blood</i> , 2014, 124, 540-540.	1.4	2
106	Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy). <i>Blood</i> , 2014, 124, 730-730.	1.4	5
107	Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1065-1065.	1.4	0
108	Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide. <i>Science Translational Medicine</i> , 2013, 5, 211ra157.	12.4	303

#	ARTICLE	IF	CITATIONS
109	Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1514-1517.	2.0	103
110	Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 647-652.	2.0	113
111	Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 602-606.	2.0	87
112	Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 655-657.	1.3	8
113	New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 224-237.	0.8	7
114	HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. <i>Blood</i> , 2012, 120, 4285-4291.	1.4	387
115	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. <i>Blood</i> , 2012, 119, 1570-1580.	1.4	221
116	Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation. <i>Seminars in Oncology</i> , 2012, 39, 683-693.	2.2	282
117	5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 754-758.	2.0	58
118	Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1404-1409.	2.0	128
119	Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. <i>Blood</i> , 2011, 117, 608-617.	1.4	69
120	Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide. <i>Mental Illness</i> , 2011, 3, e15.	0.8	66
121	Desensitization for Mismatched Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2011, 118, 1955-1955.	1.4	7
122	Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial. <i>Blood</i> , 2011, 118, 4151-4151.	1.4	11
123	High-dose cyclophosphamide for graft-versus-host disease prevention. <i>Current Opinion in Hematology</i> , 2010, 17, 493-499.	2.5	84
124	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i> , 2010, 115, 2136-2141.	1.4	107
125	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <i>Blood</i> , 2010, 115, 3224-3230.	1.4	346
126	Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 137-148.	4.2	97



#	ARTICLE	IF	CITATIONS
127	High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. <i>Immunologic Research</i> , 2010, 47, 65-77.	2.9	178
128	STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model. <i>Journal of Immunology</i> , 2010, 184, 764-774.	0.8	84
129	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 482-489.	2.0	260
130	Critical Role of CD4+Foxp3+ T Cells In Gvhd Prevention with High-Dose Posttransplant Cyclophosphamide (Cy).. <i>Blood</i> , 2010, 116, 3749-3749.	1.4	3
131	Post-Transplant Cyclophosphamide and Sirolimus Are Synergistic in Preventing Rejection and Inducing Stable Mixed Chimerism Independently of Regulatory T Cells.. <i>Blood</i> , 2009, 114, 3540-3540.	1.4	1
132	The Allogeneic Effect Revisited: Exogenous Help for Endogenous, Tumor-Specific T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 499-509.	2.0	36
133	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
134	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1279-1287.	2.0	251
135	Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). <i>Blood</i> , 2008, 112, 56-56.	1.4	6
136	Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. <i>Blood</i> , 2007, 109, 4564-4574.	1.4	28
137	Rapamycin Promotes Emergence of IL-10-Secreting Donor Lymphocyte Infusion-Derived T Cells Without Compromising Their Graft-Versus-Leukemia Reactivity. <i>Transplantation</i> , 2007, 83, 631-640.	1.0	9
138	Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).. <i>Blood</i> , 2007, 110, 173-173.	1.4	5
139	STAT3 Signaling in Donor-Derived CD4+ T-Cells Plays a Critical Role in the Induction of Acute and Chronic GVHD in Murine Models of alloBMT.. <i>Blood</i> , 2007, 110, 2179-2179.	1.4	0
140	Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 414-421.	2.0	56
141	Host-Derived Langerhans Cells Persist after MHC-Matched Allografting Independent of Donor T Cells and Critically Influence the Alloresponses Mediated by Donor Lymphocyte Infusions. <i>Journal of Immunology</i> , 2006, 177, 4414-4425.	0.8	36
142	Nonmyeloablative alternative donor transplants. <i>Current Opinion in Oncology</i> , 2003, 15, 121-126.	2.4	3
143	Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. <i>Blood</i> , 2003, 101, 1645-1652.	1.4	67
144	Donor Lymphocyte Infusions to Treat Hematologic Malignancies in Relapse after Allogeneic Blood or Marrow Transplantation. <i>Cancer Control</i> , 2002, 9, 123-137.	1.8	87

#	ARTICLE	IF	CITATIONS
145	Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 131-138.	2.0	103
146	Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. <i>Blood</i> , 2001, 98, 3456-3464.	1.4	312
147	Hormone receptor regulation of the human immunodeficiency virus type 1 and type 2 long terminal repeats. <i>Journal of Biomedical Science</i> , 1996, 3, 323-331.	7.0	8